RT Journal Article
SR Electronic
T1 High Resolution CHEST CT(HRCT) Evaluation in Patients Hospitalized with COVID-19 Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.26.20114082
DO 10.1101/2020.05.26.20114082
A1 Patel, Maulin
A1 Chowdhury, Junad
A1 Zheng, Matthew
A1 Abramian, Osheen
A1 Verga, Steven
A1 Zhao, Huaqing
A1 Patlakh, Nicole
A1 Montecalvo, Nicholas
A1 Fleece, David
A1 Cohen, Gary
A1 Kumaran, Maruti
A1 Dass, Chandra
A1 Criner, Gerard J.
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/05/28/2020.05.26.20114082.abstract
AB Introduction Currently the main diagnostic modality for COVID-19 (Coronavirus disease-2019) is reverse transcriptase polymerase chain reaction (RT-PCR) via nasopharyngeal swab which has high false negative rates. We evaluated the performance of high-resolution computed tomography (HRCT) imaging in the diagnosis of suspected COVID-19 infection compared to RT-PCR nasopharyngeal swab alone in patients hospitalized for suspected COVID-19 infection.Methods This was a retrospective analysis of 324 consecutive patients admitted to Temple University Hospital. All hospitalized patients who had RT-PCR testing and HRCT were included in the study. HRCTs were classified as Category 1, 2 or 3. Patients were then divided into four groups based on HRCT category and RT-PCR swab results for analysis.Results The average age of patients was 59.4 (±15.2) years and 123 (38.9%) were female. Predominant ethnicity was African American 148 (46.11%). 161 patients tested positive by RT-PCR, while 41 tested positive by HRCT. 167 (52.02%) had category 1 scan, 63 (19.63%) had category 2 scan and 91 (28.35%) had category 3 HRCT scans. There was substantial agreement between our radiologists for HRCT classification (κ = 0.64). Sensitivity and specificity of HRCT classification system was 77.6 and 73.7 respectively. Ferritin, LDH, AST and ALT were higher in Group 1 and D-dimers levels was higher in Group 3; differences however were not statistically significant.Conclusion Due to its high infectivity and asymptomatic transmission, until a highly sensitive and specific COVID-19 test is developed, HRCT should be incorporated into the assessment of patients who are hospitalized with suspected COVID-19.Key Question Can High Resolution CT chest (HRCT) improve diagnostic accuracy of current Nasopharyngeal swab in suspected COVID-19 patients?Bottom Line In this retrospective analysis, our novel HRCT classification identified 20% of all COVID-19 patients who had negative nasopharyngeal reverse transcriptase polymerase chain reaction (RT-PCR) tests but had HRCT findings consistent with COVID-19 pneumonia. These patients were ruled out for other infections and laboratory markers were similar to other RT-PCR positive patientsWhy Read on Our new HRCT classification when combined with RT-PCR can improve diagnostic accuracy while promptly improving triaging in COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was derived from the IRB approved Temple University Registry for COVID19 (TUIRB Protocol Number: 26854). Subsequently, a separate IRB approval was granted for chart review of HRCT scans (TUIRB protocol number: 27051). A waiver of consent was granted due to minimal risk. All identifiable personal information was removed for privacy protectionAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll deidentified data will be available upon request to the correnponding author